Analysts Offer Predictions for HRTX Q2 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for Heron Therapeutics in a report released on Monday, June 9th. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings of $0.00 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Heron Therapeutics' Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.04 EPS, FY2027 earnings at $0.21 EPS, FY2028 earnings at $0.43 EPS and FY2029 earnings at $0.44 EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to analysts' expectations of $37.08 million.

HRTX has been the subject of several other reports. Wall Street Zen raised Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Needham & Company LLC reissued a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th.

Heron Therapeutics Stock Performance

NASDAQ:HRTX traded down $0.03 on Wednesday, hitting $2.03. The stock had a trading volume of 496,766 shares, compared to its average volume of 2,230,002. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93. The firm's fifty day simple moving average is $2.01 and its two-hundred day simple moving average is $1.88. The stock has a market cap of $309.70 million, a P/E ratio of -11.28 and a beta of 1.16.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. purchased a new stake in shares of Heron Therapeutics in the fourth quarter worth $4,706,000. AIGH Capital Management LLC purchased a new stake in shares of Heron Therapeutics during the first quarter worth about $6,112,000. Palisade Capital Management LP boosted its holdings in shares of Heron Therapeutics by 34.7% during the 1st quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company's stock valued at $11,631,000 after purchasing an additional 1,360,542 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in Heron Therapeutics in the 4th quarter worth approximately $1,071,000. Finally, New York State Common Retirement Fund raised its stake in Heron Therapeutics by 32.7% during the first quarter. New York State Common Retirement Fund now owns 1,752,924 shares of the biotechnology company's stock valued at $3,856,000 after purchasing an additional 431,918 shares in the last quarter. 80.01% of the stock is owned by institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.